Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on October 21, 2013. The filing details the entry into material definitive agreements regarding amendments to existing Asset Purchase Agreements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal agreements and intellectual property transactions rather than financial performance metrics.
Material Changes and Agreements
- Buderer Amendment (Oct 21, 2013): Amended the June 11, 2013 Asset Purchase Agreement with Buderer Drug Company, Inc. The amendment modifies termination rights, allowing Buderer to terminate and request re-assignment of technology if, after five years, the Company has not initiated data-generating studies or generated royalty payments. This change grants the Company broader commercialization flexibility.
- Novel Amendment (Oct 23, 2013): Amended the October 8, 2013 Asset Purchase Agreement with Novel Drug Solutions, LLC. The scope of acquired assets was expanded to include compositions of epinephrine, Shugarcaine, phenylephrine, or lidocaine for human use. The Company also received assignment of a provisional patent application for epinephrine-based pharmaceutical compositions, including ophthalmological applications.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management outlook, or specific risk factors beyond the contractual conditions of the amendments. The primary contingency noted is the potential termination of the Buderer agreement if specific development or royalty milestones are not met within five years.
Investor Verification Checklist
- Verify the exact scope of the "epinephrine-based compounds" and ophthalmological applications assigned under the Novel Amendment.
- Confirm the specific definition of "initiated any study where data is derived" under the Buderer Amendment to assess termination risk.
- Review the original June 11, 2013 and October 8, 2013 Asset Purchase Agreements to understand the baseline terms before these amendments.
- Check subsequent filings for any updates on the status of the studies or royalty payments mentioned in the Buderer Amendment.